Hope for hunter syndrome: new drug shows promise in Long-Term trial

NCT ID NCT05594992

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study looks at the long-term safety and effectiveness of a drug called JR-141 for people with Hunter syndrome, a rare genetic disorder. About 80 participants who completed an earlier study will continue treatment. Researchers will track changes in brain function, thinking skills, and physical abilities over several years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Universitario Austral

    Buenos Aires, Argentina

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil

  • Hôpital Femme Mère Enfant

    Bron, France

  • Instituto de Genética e Erros Inatos do Metabolismo

    São Paulo, Brazil

  • Osp. Pediatrico Bambino Gesù, IRCCS

    Rome, Italy

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California, 94609, United States

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Uniwersytecki Szpital Dziecięcy

    Krakow, Poland

Conditions

Explore the condition pages connected to this study.